PrimeVigilance

Executive Summary

PrimeVigilance is a UK-based pharmacovigilance (PV) and medical information services company, founded in 2008 and operating as part of the Ergomed Group. The company provides end-to-end, technology-driven safety and risk management solutions for pharmaceutical, biotechnology, and medical device companies across the entire product lifecycle. Its expertise spans innovative drugs, generics, vaccines, and advanced therapies, positioning it as a critical partner in drug safety and regulatory compliance. With a focus on digital health, PrimeVigilance leverages technology to enhance PV processes, improving efficiency and accuracy for its clients. The company operates in a growing market driven by increasing regulatory requirements and the need for robust safety surveillance. As a private entity in Phase 1, PrimeVigilance is likely focused on expanding its client base and service offerings. Given its integration with Ergomed, it benefits from synergies in clinical research and commercial services. Future growth will depend on securing new contracts, particularly in emerging therapies such as cell and gene therapies, where specialized PV expertise is in high demand. The company's established presence and reputation in the UK and European markets provide a solid foundation for expansion.

Upcoming Catalysts (preview)

• Q4 2026Major client win in advanced therapies (cell/gene therapy)70% success
• Q2 2026Launch of AI-driven PV platform enhancement60% success
• Q3 2026Expansion into US market through strategic partnership50% success